Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5763-5771

  Cheng, Long ^a   Chen, Yuan zheng ^b   Peng, Yi ^c   Yi, Nan ^a   Gu, Xin shi ^a   Jin, Yong ^a   Bai, Xu ming ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c HUBEI CANCER HOSPITAL   (China)

Author keywords

Apoptosis; Cinobufotalin; Hepatocellular carcinoma; SphK1 and ceramide

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ANTINEOPLASTIC AGENT; CERAMIDE; CERAMIDE SYNTHASE 1; CINOBUFOTALIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; SPHINGOSINE KINASE 1; SYNTHETASE; UNCLASSIFIED DRUG; BUFADIENOLIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLTRANSFERASE; MORPHOLINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SKIP PROTEIN, HUMAN; SPHINGOSINE ACYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CERAMIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSYLTRANSFERASES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MORPHOLINES; SPHINGOSINE N-ACYLTRANSFERASE;

EID: 84940438726     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3245-1     Document Type: Article

References (44)

1. Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, et al. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract. 2005;59:1157–61.
2. Zhou P, Zhao MW, Li XX, Yu WZ, Bian ZM. Sirna targeting mammalian target of rapamycin (mtor) attenuates experimental proliferative vitreoretinopathy. Curr Eye Res. 2007;32:973–84.
3. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mtor in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007;26:611–21.
4. Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the akt/mtor pathway. Invest Ophthalmol Vis Sci. 2009;50:4429–35.
5. Emam H, Zhao QL, Furusawa Y, Refaat A, Ahmed K, Kadowaki M, et al. Apoptotic cell death by the novel natural compound, cinobufotalin. Chem Biol Interact. 2012;199:154–60.
6. Li Z, Gao H, Wang J, Qu T, Chen L, Wang Z, et al. Inhibitory effect of total bufadienolides from toad venom against h22 tumor in mice and their metabolites. Zhongguo Zhong Yao Za Zhi. 2011;36:2987–93.
7. Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat. 2001;4:368–77.
8. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004;206:169–80.
9. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, et al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via akt dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011;2:e117.
10. Kai S, Lu JH, Hui PP, Zhao H. Pre-clinical evaluation of cinobufotalin as a potential anti-lung cancer agent. Biochem Biophys Res Commun. 2014;452:768–74.
11. Zhang YM, Zhang ZQ, Liu YY, Zhou X, Shi XH, Jiang Q, et al. Requirement of galphai1/3-gab1 signaling complex for keratinocyte growth factor-induced pi3k-akt-mtorc1 activation. J Invest Dermatol. 2015;135:181–91.
12. Yang L, Zheng LY, Tian Y, Zhang ZQ, Dong WL, Wang XF, Zhang XY, Cao C. C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. Exp Cell Res 2015.
13. Yu T, Li J, Sun H. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother Pharmacol. 2010;66:999–1003.
14. Taipale J, Beachy PA. The hedgehog and wnt signalling pathways in cancer. Nature. 2001;411:349–54.
15. Altura BM, Shah NC, Shah GJ, Zhang A, Li W, Zheng T, et al. Short-term mg deficiency upregulates protein kinase c isoforms in cardiovascular tissues and cells; relation to nf-kb, cytokines, ceramide salvage sphingolipid pathway and pkc-zeta: hypothesis and review. Int J Clin Exp Med. 2014;7:1–21.
16. Gong L, Yang B, Xu M, Cheng B, Tang X, Zheng P, et al. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol. 2014;73:69–77.
17. Merrill Jr AH, van Echten G, Wang E, Sandhoff K. Fumonisin b1 inhibits sphingosine (sphinganine) n-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem. 1993;268:27299–306.
18. Soriano JM, Gonzalez L, Catala AI. Mechanism of action of sphingolipids and their metabolites in the toxicity of fumonisin b1. Prog Lipid Res. 2005;44:345–56.
19. Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC, Yang YJ, Gu ZP. Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? Cell Biochem Biophys 2012.
20. Ichihashi M. Uv-induced skin damage and photo-allergic disease. Arerugi. 2007;56:670–8.
21. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, et al. Involvement of pi3k/pten/akt/mtor pathway in invasion and metastasis in hepatocellular carcinoma: association with mmp-9. Hepatol Res. 2009;39:177–86.
22. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–27.
23. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16.
24. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J. 1998;335(Pt 3):465–80.
25. Veldman RJ, Klappe K, Hoekstra D, Kok JW. Metabolism and apoptotic properties of elevated ceramide in ht29rev cells. Biochem J. 1998;331(Pt 2):563–9.
26. Babia T, Veldman RJ, Hoekstra D, Kok JW. Modulation of carcinoembryonic antigen release by glucosylceramide–implications for ht29 cell differentiation. Eur J Biochem. 1998;258:233–42.
27. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 1995;82:405–14.
28. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 1996;15:2417–24.
29. Myrick D, Blackinton D, Klostergaard J, Kouttab N, Maizel A, Wanebo H, et al. Paclitaxel-induced apoptosis in jurkat, a leukemic t cell line, is enhanced by ceramide. Leuk Res. 1999;23:569–78.
30. Yu T, Li J, Qiu Y, Sun H. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (pdmp) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, jnk activation, and inhibiting pi3k/akt activation. Mol Cell Biochem. 2011;361:47–54.
31. Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, Sietsma H, et al. Pdmp sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther. 2006;5:593–601.
32. Sietsma H, Veldman RJ, Kolk D, Ausema B, Nijhof W, Kamps W, et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res. 2000;6:942–8.
33. Vadas M, Xia P, McCaughan G, Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta. 2008;1781:442–7.
34. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting sphk1 as a new strategy against cancer. Curr Drug Targets. 2008;9:662–73.
35. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50–60.
36. Stevenson CE, Takabe K, Nagahashi M, Milstien S, Spiegel S. Targeting sphingosine-1-phosphate in hematologic malignancies. Anticancer Agents Med Chem. 2011;11:794–8.
37. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the s1p/edg1 axis in hepatocellular carcinoma. Liver Int. 2012;32:331–8.
38. Hay N. The akt-mtor tango and its relevance to cancer. Cancer Cell. 2005;8:179–83.
39. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39:486–92.
40. Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol. 2008;49:1–5.
41. Altomare DA, Testa JR. Perturbations of the akt signaling pathway in human cancer. Oncogene. 2005;24:7455–64.
42. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2a. J Biol Chem. 1993;268:15523–30.
43. Law B, Rossie S. The dimeric and catalytic subunit forms of protein phosphatase 2a from rat brain are stimulated by c2-ceramide. J Biol Chem. 1995;270:12808–13.
44. Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem. 1994;269:19605–9.